Cerdulatinib hydrochloride

Research use only, not for human use.

Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively.

Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.

Cell Viability Assay Cell Line:SU-DHL4; SU-DHL6; Ramosand and Daudi cells Concentration:0, 1, 3 μM Incubation Time:48 hours Result:Inhibits cells viability with the IC50s of 0.73-1.39 μM.Apoptosis Analysis Cell Line:SU-DHL4, SU-DHL6, and Ramos cells Concentration:0, 1.6, 5.0, 15 μM Incubation Time:72 hours Result:Induced SU-DHL4, SU-DHL6, and Ramos cells apoptosis.

Animal Model:Female Lewis rats (7-8 weeks old; 159-187 g) are immunizedDosage:0, 0.5, 1.5, 3, 5?mg/kg Administration:Oral gavage twice daily for 2 weeks Result:Modulated inflammation in the rat CIA treatment model.Affected anticollagen antibody formation.Animal Model:Balb/c mice are received BCR stimulation Dosage:0, 1, 5, 15, 20, 30?mg/kg Administration:Oral gavage twice daily for 5 days Result:Suppressed upregulation of splenic B-cell surface CD80/86 and CD69 by＞60%.Inhibited mouse splenomegaly in a dose- and concentration-dependent manner.

——

Others

Other Targets

c-Fms| MST1| ARK5| MLK1| Tyk2

Cancer|Inflammation/Immunology

——

1369761-01-2

482

C20H28ClN7O3S

>98% (HPLC)

In Vitro:?DMSO : 20 mg/mL (41.49 mM)

Cl.CCS(=O)(=O)N1CCN(CC1)C1=CC=C(NC2=NC(NC3CC3)=C(C=N2)C(N)=O)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years